Cover Image
市場調查報告書

生長激素缺乏症:開發中產品分析

Growth Hormone Deficiency - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 192612
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
生長激素缺乏症:開發中產品分析 Growth Hormone Deficiency - Pipeline Review, H2 2015
出版日期: 2015年10月14日 內容資訊: 英文 111 Pages
簡介

生長激素 (GH) 分泌不全症 (缺乏症) 是腦下垂體無法產生足夠的成長荷爾蒙所造成的。會造成成長會一般緩慢。症狀有能量低落、體力及運動耐力低落、肌肉量減少、體重增加(尢其是腹部週圍)、造成社會性行動變化的不安感、抑鬱感、悲傷、皮膚敏感或皮膚乾燥等。治療有荷爾蒙劑和荷爾蒙類似物質等。

本報告提供生長激素缺乏症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

生長激素缺乏症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 階段不明的產品

開發中的產品:各企業

開發治療藥的企業

  • Aeterna Zentaris Inc.
  • Aileron Therapeutics, Inc.
  • Ascendis Pharma A/S
  • Biogenomics Limited
  • Bolder Biotechnology, Inc.
  • Braasch Biotech LLC
  • Carlina Technologies SAS
  • Critical Pharmaceuticals Limited
  • Delpor, Inc.
  • Flamel Technologies S.A.
  • Genexine, Inc.
  • HanAll Biopharma Co., Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Inbiopro Solutions Pvt. Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • LG Life Sciences Limited
  • OPKO Health, Inc.
  • Pfenex Inc.
  • Prometheon Pharma, LLC
  • Teva Pharmaceutical Industries Limited
  • Versartis, Inc.
  • XL-protein GmbH

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ACP-001
  • albutropin
  • ALRN-5281
  • BBT-031
  • CP-016 SR
  • CP-024
  • GXH-9
  • HL-032
  • HM-10560A
  • IBPB-003HH
  • macimorelin acetate
  • MOD-4023
  • Pegylated Somatropin
  • somatotropin SR
  • somatotropin SR
  • somatropin
  • somatropin
  • somatropin
  • somatropin
  • somatropin biobetter
  • somatropin biobetter
  • somatropin pegol
  • somatropin SR
  • somavaratan
  • Vaccine for Growth Hormone Deficiencies
  • XL-020

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6857IDB

Summary

Global Markets Direct's, 'Growth Hormone Deficiency - Pipeline Review, H2 2015', provides an overview of the Growth Hormone Deficiency's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Growth Hormone Deficiency pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Growth Hormone Deficiency
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Deficiency pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Growth Hormone Deficiency Overview
  • Therapeutics Development
    • Pipeline Products for Growth Hormone Deficiency - Overview
    • Pipeline Products for Growth Hormone Deficiency - Comparative Analysis
  • Growth Hormone Deficiency - Therapeutics under Development by Companies
  • Growth Hormone Deficiency - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Growth Hormone Deficiency - Products under Development by Companies
  • Growth Hormone Deficiency - Companies Involved in Therapeutics Development
    • Aeterna Zentaris Inc.
    • Aileron Therapeutics, Inc.
    • Ascendis Pharma A/S
    • Biogenomics Limited
    • Bolder Biotechnology, Inc.
    • Braasch Biotech LLC
    • Carlina Technologies SAS
    • Critical Pharmaceuticals Limited
    • Delpor, Inc.
    • Flamel Technologies S.A.
    • Genexine, Inc.
    • HanAll Biopharma Co., Ltd.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Inbiopro Solutions Pvt. Ltd.
    • JCR Pharmaceuticals Co., Ltd.
    • LG Life Sciences Limited
    • OPKO Health, Inc.
    • Pfenex Inc.
    • Prometheon Pharma, LLC
    • Teva Pharmaceutical Industries Limited
    • Versartis, Inc.
    • XL-protein GmbH
  • Growth Hormone Deficiency - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • albutropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALRN-5281 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-031 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CP-016 SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CP-024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GXH-9 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HL-032 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-10560A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IBPB-003HH - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • macimorelin acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-4023 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pegylated Somatropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatotropin SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatotropin SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin biobetter - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin biobetter - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somavaratan - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Growth Hormone Deficiencies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XL-020 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Growth Hormone Deficiency - Recent Pipeline Updates
  • Growth Hormone Deficiency - Dormant Projects
  • Growth Hormone Deficiency - Discontinued Products
  • Growth Hormone Deficiency - Product Development Milestones
    • Featured News & Press Releases
      • Oct 01, 2015: Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study at Late-Breaker Session at ESPE Annual Meeting
      • Sep 18, 2015: Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children
      • Sep 10, 2015: Versartis Initiates Phase 2 Trial of Monthly Somavaratan in Adults With Growth Hormone Deficiency
      • Sep 08, 2015: Versartis Announces Agenda and Event Details for Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency
      • Aug 05, 2015: Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology
      • Aug 04, 2015: Versartis Abstract Accepted for Late-Breaker Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology
      • Jul 30, 2015: Ascendis Pharma Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency
      • Jul 10, 2015: Opko Announces Completion Of Enrollment In Phase 3 Trial Of Hgh-Ctp In Growth Hormone Deficient Adults
      • Jul 06, 2015: Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial
      • Jun 25, 2015: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Growth Hormone Deficiency, H2 2015
  • Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Growth Hormone Deficiency - Pipeline by Aeterna Zentaris Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by Aileron Therapeutics, Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by Ascendis Pharma A/S, H2 2015
  • Growth Hormone Deficiency - Pipeline by Biogenomics Limited, H2 2015
  • Growth Hormone Deficiency - Pipeline by Bolder Biotechnology, Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by Braasch Biotech LLC, H2 2015
  • Growth Hormone Deficiency - Pipeline by Carlina Technologies SAS, H2 2015
  • Growth Hormone Deficiency - Pipeline by Critical Pharmaceuticals Limited, H2 2015
  • Growth Hormone Deficiency - Pipeline by Delpor, Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by Flamel Technologies S.A., H2 2015
  • Growth Hormone Deficiency - Pipeline by Genexine, Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Growth Hormone Deficiency - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
  • Growth Hormone Deficiency - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
  • Growth Hormone Deficiency - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015
  • Growth Hormone Deficiency - Pipeline by LG Life Sciences Limited, H2 2015
  • Growth Hormone Deficiency - Pipeline by OPKO Health, Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by Pfenex Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by Prometheon Pharma, LLC, H2 2015
  • Growth Hormone Deficiency - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Growth Hormone Deficiency - Pipeline by Versartis, Inc., H2 2015
  • Growth Hormone Deficiency - Pipeline by XL-protein GmbH, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Growth Hormone Deficiency Therapeutics - Recent Pipeline Updates, H2 2015
  • Growth Hormone Deficiency - Dormant Projects, H2 2015
  • Growth Hormone Deficiency - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Growth Hormone Deficiency, H2 2015
  • Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top